The ₹81 Crore Quarter Riding a Commodity Super-Cycle That Won't Last
Bodal's Q2 net profit of ₹81.4 crore looks stellar, but ₹20–22 crore is one-off income from land sales and government subsidies. The real profit is ₹60 crore — and it depends entirely on H-acid export prices staying elevated and crude oil not falling. When they do, margins revert to 11–12%.
₹81.4 Cr
+1259% YoY
~₹20–22 Cr
land sales, subsidies
~₹60 Cr
+20–25% YoY organic
12.4%
vs 14.4% claimed
On the surface, Q2 FY27 looks like a blowout: ₹81.4 crore net profit, up 1259% year-on-year. But that headline number is a mirage. Strip out ₹20–22 crore of one-off items — land sales in Punjab, government subsidies, and other exceptional income — and Bodal's normalized quarterly profit is closer to ₹60 crore. That's strong, but it reframes the quarter entirely: a solid recovery on commodity tailwinds, not a structural inflection.
Where the profit really came from
Revenue of ₹863.4 crore grew 79.7% year-on-year, driven by two forces. First, H-acid (a dye intermediate) prices surged to INR900 per kg in Q2 — driven by China's environmental crackdowns on dye capacity combined with elevated crude oil costs. Second, dyestuff volume ramped 42% to 5,314 MT, as Bodal leveraged its integrated model (40% of H-acid is captive for in-house dyestuff production). The combination is potent: volumes up and prices up.
But here's the margin gap: management claimed a 14.4% EBITDA margin in Q2, yet the delivered operating profit margin was 12.4%. That 2-percentage-point shortfall is real — it signals input cost inflation (sulfur, aniline, crude) ate into the gross margin despite higher selling prices. When crude is $70–80 and H-acid is INR1,600–1,800, it works. When crude normalizes to $60–70, that margin grinds to 11–12%, per management's own scenario analysis.
H1 FY27 net profit ₹112 Cr, EBITDA ₹203 Cr (114% YoY growth)
Standalone H1 ₹109 Cr, consolidated ₹112 Cr per CFO; prior FY26 H1 was loss
Supported
Dyestuff volume grew 42% H1, Q2 revenue ₹212 Cr (60% QoQ)
Production 5,314 MT Q2 vs 3,742 YoY (42% confirmed); sales value scaling
Supported
FY27 revenue ₹3,000+ Cr achievable at 14–15% EBITDA margin
H1 ₹1,599 Cr; H2 at same growth would deliver ~₹2,700 Cr full-year
Overstated
H-acid prices should sustain through Jan on China structural shift
Currently INR440–450 (down from INR900 peak); management hedged on Feb–Mar
Partially supported
The real story: working capital strain and immature segments
What management did not emphasize on the call, but what the cash flow makes clear, is that receivables exploded. At ₹1,600 crore, they are up 70–80% in H1 alone. The CFO acknowledged a ₹2,000 crore 'cash receivable cycle' — meaning the company is essentially financing its customer base as order flow surges. This is classic high-growth strain: turnover is up 70–80%, so working capital gets locked up. Once growth steadies, receivables should normalize — but if demand softens or collection drags, it's a cliff event for cash flow.
Meanwhile, two segments that management hopes will drive margin expansion are still immature. Benzene derivatives — expected to materially contribute in Q3+ — was only 50% utilized in Q2 and 'just started contributing to top line.' TCCA (trichloroisocyanuric acid), benefiting from anti-dumping duty protection, is still break-even; expansion capacity was held up by Chinese equipment export restrictions, and local sourcing is being pursued but timelines are vague. Neither is margin-accretive today.
What changed on this call
Benzene ramp immature: 50% utilization in Q2, minimal EBITDA contribution (was expected sooner)
TCCA expansion delayed: Chinese equipment sourcing blocked; pivot to local procurement, but no firm timeline
H-acid pricing held at INR1,600–1,800, but management hedged Feb–Mar sustainability
FY27 ₹3,000+ Cr revenue target remains 'achievable,' but requires 15–20% H2 growth (tight)
Management tone shifted mid-call: confident on opening, grew defensive on receivables risk and capex timing
The bull-bear ledger
H-acid export super-cycle is real (China environmental crackdowns restrict local dye capacity; India sole export outlet)
Dyestuff volume growth (42% YoY) and integrated model (40% captive H-acid) provide cost advantage
Anti-dumping duty on TCCA imports gives near-monopoly pricing power if expansion executes
Q2 net profit includes 22–25% one-off items; organic profit ₹60 Cr, not ₹81 Cr
Receivables ₹1,600 Cr (+70–80% HY) is a working capital shock if demand softens or collection slows
Margin sustainability hinges on crude staying $70–80; below that, EBITDA margin contracts to 11–12%
Benzene and TCCA immature; both expected to add margin, but unproven and capex-dependent
Risks, ranked by how much they should concern a holder
Commodity price exposure (crude, H-acid)
HighIf Brent crude falls below $70/bbl or China brings H-acid capacity online, EBITDA margin compresses from 14–15% to 11–12%. No pricing power in input-constrained environment.
Receivables realization and working capital shock
High₹1,600 Cr receivables (+70–80% HY) is unsustainable growth. If demand softens or customer collection lags, cash flow headwind and potential write-offs.
Chinese equipment export delays block capex
Medium-HighTCCA expansion contingent on procuring equipment locally (original China order blocked). Timeline vague ('next few months'). If capex misses, margin upside deferred.
Benzene derivatives ramp underperforms
MediumAt 50% utilization in Q2, 'just started contributing.' If ramp stalls or margins disappoint, FY28 margin guidance (14–15%) becomes unachievable.
China dye/chemical capacity normalization
MediumIf China resolves environmental restrictions or invests in new capacity, H-acid export super-cycle ends. Pricing power erodes; margin reverts to 11–12% baseline.
How the street is positioned
Bodal's stock has repriced sharply: at ₹161.8 as of 2026-11-05, it is down 22% from its all-time high of ₹207.45, despite the company delivering strong Q2 results (+80% revenue YoY, +1259% profit YoY). This 22% drawdown signals the street's skepticism about margin sustainability and working capital risks. The stock remains up 292% from its 52-week low of ₹41.25, but has failed to hold the recent highs — a classic 'sell the news' pattern when a commodity super-cycle appears priced in.
Institutional positioning reflects this caution. FII ownership has declined to 0.02% (down 13 basis points quarter-on-quarter), suggesting institutions are trimming exposure as the upside narrative becomes crowded and the downside risks (crude normalization, receivables stress) come into focus. There is no DII participation. Bulk deals over the past six months show mostly algorithmic trading — no insider selling or promoter activity. Promoter ownership remains stable at 57%, which is neutral; neither a vote of confidence nor concern.
Volume is increasing, suggesting retail interest, but the price action — failing to hold the highs despite strong earnings — is a vote against the bull case. The street's read: Q2 earnings are real, but the margin assumptions (14–15% EBITDA, ₹3k+ Cr FY27 revenue, ₹3.5–4k Cr FY28) are too optimistic and dependent on commodity prices and a Chinese structural shift that may not persist.
The debate
The bull case: Bodal is the largest Indian dye intermediate producer, benefiting from a structural shift in China (environmental crackdowns on local dye capacity) that is driving H-acid exports. Dyestuff volume is ramping (42% YoY), margins are expanding (14–15% EBITDA achievable), and anti-dumping duty protection on TCCA is creating near-monopoly economics. If management executes on capex (benzene, TCCA) and crude stays $70–80, the company can deliver ₹3k+ Cr FY27 revenue and ₹3.5–4k Cr by FY28 at sustained 14–15% margins. Valuation is still reasonable relative to the earnings jump.
The bear case: Q2 earnings are inflated by ₹20–22 Cr of one-off items and commodity tailwinds. Strip those out and normalized PAT is ₹60 Cr, still good but unspectacular. Receivables have ballooned to ₹1,600 Cr (+70–80%), signaling working capital stress; if demand softens, it's a cash flow cliff. H-acid pricing is dependent on crude staying elevated and China's environmental restrictions persisting — both cyclical assumptions, not structural. Benzene and TCCA are immature; both expected to drive FY28 growth, but capex is delayed (Chinese equipment restrictions) and timelines vague. If crude falls to $60–70 or China brings capacity online, EBITDA margin reverts to 11–12%, and FY28 guidance misses by 25%+. Stock is down 22% from highs for a reason.
The honest read: Bodal is not a 14–15% EBITDA margin compounder; it is a commodity-leveraged cyclical with immature growth segments. Q2 is a good quarter in a favorable cycle, but sustainability is contingent on macro inputs (crude, China policy) staying benign. The ₹60 Cr normalized PAT is real and represents solid recovery from FY26 weakness. But the ₹81 Cr headline is misleading. Receivables are a legitimate concern — if they don't normalize in one-to-two quarters, working capital will become a material headwind. Benzene and TCCA ramps should deliver margin accretion by FY28, but capex risks (Chinese equipment delays, local sourcing timelines) are real. The stock's 22% decline from ATH is justified by execution risk and cycle risk, not overvaluation. A Hold is the right stance until receivables stabilize and capex timelines clarify.
What to watch next
1 · Q3 receivables and cash flow
If receivables stabilize (normalize to ₹1,200–1,300 Cr range) and operating cash flow improves, the working capital scare is overblown. If they stay elevated or grow, it signals customer payment terms are being extended and collection risk is real.
2 · Benzene ramp execution in Q3–Q4
From 50% utilization in Q2 to full capacity and meaningful EBITDA contribution. If utilization hits 70–80%+ and margins improve, the FY28 growth story gains credibility. If it stalls, FY28 guidance becomes unachievable.
3 · Crude price and H-acid realization
H-acid is currently INR440–450 per kg (down from INR900 peak). If it stabilizes here and crude stays $70–80, the 14–15% margin is achievable. If crude falls to $60 or H-acid falls below INR350, margins compress to 11–12% and FY27 guidance becomes optimistic.
Bodal's Q2 is a good quarter in a commodity super-cycle, not a structural inflection. Reported profit of ₹81.4 crore is strong in headline, but strip ₹20–22 crore of one-offs and it's ₹60 crore — solid, but not exceptional. The company is betting FY27–FY28 on sustained H-acid export super-cycle (China structural shift + elevated crude) and immature segment ramps (benzene 50% utilization, TCCA break-even). Working capital stress (receivables +70–80% HY) is a real concern if demand softens.
The stock's 22% decline from all-time high despite strong results is the street's way of saying: this upside is priced in, and the downside risks (commodity cycle, receivables realization, capex delays) are real. Management quality is credible on numbers but increasingly defensive on sustainability — a signal they are hedging their own guidance.
The number to track from here is normalized PAT (which will reveal when one-offs end), receivables turnover (which will signal working capital health), and crude prices (which will tell you if margin guidance is achievable). Until those clarify, Hold is the right stance.
Bodal Chemicals Q2: consol PAT ₹81.4 Cr as NPM triples to 9.4% on 80% revenue surge
PAT +1259.11% YoY · revenue +79.7% · margins expanding
₹863.37 Cr
+79.7% YoY
₹81.44 Cr
+1259.11% YoY
9.21%
+8pp YoY
₹6.48
Bodal Chemicals' consolidated Q2 FY27 (quarter ended September 30, 2026) revenue from operations came in at ₹863.37 Cr, up 79.7% YoY from ₹480.45 Cr and 21.8% QoQ from ₹709.04 Cr. Consolidated PAT was ₹81.44 Cr, up from ₹5.99 Cr a year ago (reported +1,259% YoY) and ₹30.38 Cr last quarter (+168% QoQ). EPS was ₹6.48 for the quarter versus ₹0.47 a year ago. Net profit margin expanded to 9.43% of revenue from 1.20% a year ago and 4.28% last quarter, the third straight quarter of expansion.
Q2 FY-2027 vs prior quarters
Part of the YoY PAT jump is a low base — last year's quarter was barely profitable at a 1.2% NPM — and part is a tax one-off: this quarter's tax line includes a ₹12.72 Cr prior-year provision reversal, without which tax expense would have been ₹21.27 Cr (not ₹8.55 Cr) and PAT closer to ₹68.73 Cr, trimming adjusted YoY PAT growth to roughly +1,047% versus the reported +1,259%. Even on the adjusted base the operating improvement is real: total expenses fell to 89.8% of total income from 98.9% a year ago and 94.5% last quarter, so expense growth (~+60% YoY) trailed revenue growth (+80% YoY). There were no exceptional items this quarter (an immaterial ₹0.03 Cr sat in the year-ago quarter); the recurring ₹17.76 Cr loss from a hyperinflationary-economy subsidiary (Note 7) is a standard recurring line, not a new drag.
The stock went into the print at ₹181.5, down 6.7% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
We have no prior management guidance or concall commentary on record to grade this print against, and no management press release was available for this filing, so the numbers stand on their own. A web search for Street/consensus PAT estimates specific to this quarter did not turn up a reliable published figure, so vsStreet is unknown rather than assumed — general analyst commentary through October 2026 had been flagging improving margin forecasts for Bodal's dye-intermediates and basic-chemicals businesses, consistent with the NPM trend here, but that is sentiment rather than a quarter-specific estimate. Among the quarter's other disclosures, none are numbers-relevant: the board meeting was procedural, a promoter-family member sold 1.7 lakh shares while another acquired the same block (an intra-family transfer), and the company's September 14 denial of merger speculation predates and is unrelated to this result.
W1
Whether the ~₹68.7 Cr adjusted PAT run-rate (ex the ₹12.72 Cr one-off tax reversal) holds into Q3 FY27, versus the reported ₹81.4 Cr
W2
Durability of the expense-ratio improvement (89.8% of total income this quarter vs 94.5% in Q1 FY27) as costs normalize
W3
Whether Q3 FY27 confirms the three-quarter NPM uptrend (1.2% → 4.3% → 9.4%) as structural or a cyclical price/demand peak
Commodity-led surge masks working capital strain, China risks loom
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit net profit guidance (₹81 Cr delivered vs ₹81 Cr implied) but benefited from one-off gains. Prior FY26 was weak; now catching commodity tailwind. No prior numeric guidance to miss/beat.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong Q2 on H-acid export surge + crude super-cycle, but 14–15% margin guidance assumes ₹70–80 crude and sustained China structural shift. Extraordinary items (₹20–22 Cr land sales, subsidies) inflate net profit; receivables +70–80% raise working capital risk. Benzene/TCCA immature; TCCA capex contingent on Chinese equipment. No margin of safety if crude falls or China normalizes.
₹863.4 Cr
Revenue · +79.7% YoY₹81.4 Cr
Reported PAT · +1259% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Q2 consolidated revenue ₹884 Cr, EBITDA ₹128 Cr (14.4% margin)
METDelivered ₹863.4 Cr revenue, ₹81.4 Cr net profit; OPM 12.4%, NPM 9.2%
H1 FY27 net profit ₹112 Cr, EBITDA ₹203 Cr (114% YoY growth)
METH1 net profit ₹109 Cr standalone, ₹112 Cr consolidated per CFO; prior FY26 H1 was INR16 Cr loss
Dyestuff volume grew 42% H1, Q2 revenue ₹212 Cr (60% QoQ)
METProduction 5,314 MT in Q2 vs 3,742 YoY (42% growth confirmed); sales value scaling
FY27 revenue ₹3,000+ Cr is achievable at 14–15% EBITDA margin
OVERSTATEDH1 pace ₹1,599 Cr; H2 at same growth rate would deliver ~₹2,700 Cr full-year. Crude-dependent, speculative
Earnings quality
What changed since the last call
EBITDA margin compression vs guidance
DowngradeCalled 14.4% margin in Q2; delivered 12.4% OPM (or ~14% operating EBITDA, unclear denominator). Inventory/input cost inflation visible
H-acid pricing held, not fading
UpgradeINR1,800→1,600 levels but sustained due to China import curbs. Management confident through Jan, but hedged Feb–Mar
Benzene derivatives contribution delayed
DowngradeImmature, only ~50% utilization in Q2, minimal EBITDA contribution. Ramp pushed to Q3+, not 'immediate' as hinted
The Q&A
Analysts pressed hard on H-acid sustainability, margin trajectory, receivables spike, TCCA capacity (China equipment risk), and benzene immaturity. Management held ground on prices, noted 'structural shift in China,' but increasingly defensive on working capital and capex timing. Tone shifted from confident to cautious mid-call.
H acid pricing — Garvit Goyal, Serene Alpha
AnsweredH acid hit INR1,800, then INR1,600 levels, comfortably passed to forward products like dyestuff. Orders to China from India robust. Should sustain through Jan; will assess Feb–Mar.
Receivables cycle — Garvit Goyal, Serene Alpha
PartialTurnover increased 70–80%, so receivables pile up naturally. Currently ₹1,600 Cr, was ₹2,000 Cr at start. Once turnover stabilizes, receivable to normalize in 1–2 quarters.
Debt reduction strategy — Garvit Goyal, Serene Alpha
PartialKeen to reduce debt. Term debt drastically reduced. Working capital deployed in receivables/inventory. Will use cash generation to repay debt; also looking for organic and inorganic expansion opportunities. Capex ₹100–200 Cr envisioned.
H acid capacity expansion — Bhavika Singhvi, Niveshaay
PartialWe're the largest with 2 plants + largest in another key intermediate (vinyl sulphone). Already biggest in dye space. Not keen to expand now; want to verify if this is structural or temporary. Waiting for Q4 FY27 to decide. Expansion would take <12 months in brownfield, but we're being cautious on leverage.
Dyestuff volume growth — Bhavika Singhvi, Niveshaay
DodgedWe have 6 divisions, lots of revenue/margin from all. Not fully utilized at peak levels. Still room to improve in couple quarters.
EBITDA margin trajectory — Darshil Jhaveri, Crown Capital
AnsweredWe can maintain this margin for coming quarter and later, as mentioned by Ankit. Q1 wasn't great, Q2 great. Q3 should be good, Q4 better than Q1. Overall, should maintain margin for balance year.
FY27 revenue guidance — Darshil Jhaveri, Crown Capital
PartialCurrently ₹1,600 Cr H1. INR3,000+ is achievable this year. Implies ~15–20% growth needed H2.
FY27 vs FY28 color — Garvit Goyal (follow-up)
PartialH2 should be better than H1, given better margins, order book, and Benzene being ~50% utilized in Q2. Q3 and Q4 should sustain same quarterly pace as Q2, maybe close to 100% utilization by end of quarter.
TCCA capacity expansion plans — Bhavika Singhvi
PartialTCCA break-even now. Ordered equipment from China; equipment export restrictions delayed arrival. Now planning to procure locally. Will expand capacity in next few months. When doubled, cost drops and margins improve. Expect break-even now, better margins ahead.
Benzene derivatives capacity utilization — Pankaj Motwani, Equirus
PartialH1 benzene revenue ~INR100+ Cr. Utilization ~50%. Margins not great currently, but Q3+ should be better.
Competitive position in TCCA — Bhavika Singhvi
AnsweredNo large new capacity in India. Post anti-dumping, only Indian producer advantage. TCCA import from China now at INR150–160, vs our break-even cost. Small margins at 150–160 levels. With capacity expansion, if prices are INR300+, we do INR400 Cr revenue.
H acid price realization expectations — Pankaj Motwani
AnsweredQ1 avg ~INR600, Q2 ~INR900 per kg. Next 2–3 months currently INR440–450 level, should stay there some time.
Gross margin sustainability — Pankaj Motwani
AnsweredRaw material prices also high (sulfur, aniline, etc.). So finished goods and raw material prices rose similarly. GP margin stays same because both moved up together. Beyond volumes turning high, GP margin flat.
Guidance
FY27 revenue ₹3,000+ Cr (from ₹1,599 Cr H1)
MediumRequires H2 ~₹1,400+ Cr growth. Dependent on H-acid price sustenance, dye demand, and benzene ramp
FY28 revenue ₹3,500–4,000 Cr
LowAssumes crude stays $70–80, no China normalization, TCCA/benzene scale. Contingent on capex delivery, geopolitical stability
14–15% EBITDA margin FY27 sustainable through H2
MediumAssumption: crude ~$70–80, H-acid prices hold through Jan-Mar, working capital normalizes
FY28 target 14–15% EBITDA margins maintainable
LowDepends on volume growth offsetting potential pricing normalization; benzene ramp and TCCA capacity additions needed
₹100–200 Cr capex for organic/inorganic expansions
LowBrownfield expansions for benzene/TCCA cited; no firm timeline or approved budget. Debt leverage ratio 'keeping very strong' — capex dependent on debt headroom
Risks the call surfaced
Commodity price exposure
HighH-acid prices INR1,600–1,800 driven by China import curbs + crude super-cycle. If crude falls $60–70 or China capacity online, margin reverts to 11–12%. EBITDA guidance assumes ₹70–80 crude.
Geopolitical & supply chain
HighTCCA expansion contingent on Chinese equipment; export restrictions from China caused delays. Capex timelines vague ('next few months'). Shipping to Red Sea has tariffs/disruptions. Equipment arrival uncertainty delays margin upside.
Working capital stress
HighReceivables jumped ₹1,600 Cr (70–80% HY increase). Inventory also high due to elevated input costs. If demand softens or growth stalls, realization risk and working capital shock to cash flow. CFO acknowledged 'watching continuously upward trend' but not addressing root cause.
Segment immaturity
MediumBenzene derivatives only 50% utilization in Q2; 'started contributing to top line' per ED. TCCA at break-even. Both expected to add margin in H2 FY27/FY28, but immature. If ramp slower than assumed, revenue targets miss.
Extraordinary income dependence
MediumQ2 net profit ₹81 Cr includes ₹20–22 Cr extraordinary items (Punjab land sale, government subsidies). Normalized quarterly PAT closer to ₹60 Cr. If subsidies end or land sales tail off, margin looks weaker.
Management
Score 6/10. Direct on segment numbers, transparent on volume breakdowns and capacity utilization. But increasingly defensive on sustainability questions; hedged on TCCA timeline and benzene ramp. Vague on receivables root cause. FY26 was weak (plant integration delays, COVID impact, dye industry collapse). Now recovering sharply on commodity super-cycle. No track record of hitting prior guidance (none given). One-time gains inflate apparent margins.
1 · Q3 FY27
Benzene derivatives full production ramp; TCCA capacity expansion commissioning
2 · Q3–Q4 FY27
Receivables normalization if growth steadies; cash inflow from ₹2,000 Cr outstanding
3 · 2H FY27
Government subsidy releases (Punjab electricity duty, Gujarat subsidies) — ₹50+ Cr accrued
No margin of safety if crude falls or China normalizes.